Antidepressants and Road Safety: A Forensic Toxicological Perspective Based on Observational Data and Current Evidence
Pharmaceuticals · 20.07.2026 · 19 (7) · 1118
DOI: 10.3390/ph19071118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 20.07.2026. Verfasst von Davide Filardi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Facu…. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Antidepressants are widely prescribed medications that may affect psychomotor performance and driving ability depending on their pharmacological profile. This study investigated the prevalence and patterns of antidepressant use among drivers undergoing forensic toxicological evaluation and explored their potential implications for road safety.
Methods
An observational study was conducted on n = 6316 drivers undergoing forensic toxicological assessment following licence suspension for driving under the influence (DUI) of alcohol and/or drugs between January 2023 and December 2025. Reported antidepressants were classified into selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), serotonin antagonist and reuptake inhibitors (SARIs), tricyclic antidepressants (TCAs), norepinephrine–dopamine reuptake inhibitors (NDRIs), noradrenergic and specific serotonergic antidepressants (NaSSAs), and monoamine oxidase inhibitors (MAOIs). Distribution patterns were analysed descriptively and discussed considering the available literature.
Results
Antidepressant use was reported by n = 132 participants (2.1%). SSRIs were the most common class (44.0%), followed by SNRIs (26.5%) and SARIs (17.4%). TCAs (6.1%), NDRIs (3.7%), and NaSSAs (2.3%) were less common, while no MAOI use was reported. Among antidepressant users, n = 28 individuals (21.2%) tested positive for other psychoactive substances, including benzodiazepines, cocaine, and cannabinoids.
Conclusions
The use of antidepressants was relatively uncommon in the study population. However, clinical evaluation remains important, particularly at the start of treatment and during dose adjustments to determine the potential for an increased risk while driving. Further studies integrating toxicological analyses and clinical data are needed to better define the relationship between antidepressant exposure, polysubstance use, and road safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Forensic Toxicology, Section of Legal Medicine, Social Security and Forensic Toxicology, Department of Biomedicine and Prevention, Faculty of Medicine and Surgery, University of Rome Tor Vergata, Via Montp…
- PhD School in Medical-Surgical Applied Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
ORCID-Profile: Davide Filardi, Francesca Vernich, Federico Mineo, Roberta Tittarelli
Zitieren
APA
Filardi, D., Vernich, F., Mineo, F., Mannocchi, G., & Tittarelli, R. (2026). Antidepressants and Road Safety: A Forensic Toxicological Perspective Based on Observational Data and Current Evidence. Pharmaceuticals, 19(7), 1118. https://doi.org/10.3390/ph19071118
Vancouver
Filardi D, Vernich F, Mineo F, Mannocchi G, Tittarelli R. Antidepressants and Road Safety: A Forensic Toxicological Perspective Based on Observational Data and Current Evidence. Pharmaceuticals. 2026;19(7):1118. doi:10.3390/ph19071118
BibTeX
@article{Filardi2026,
author = {Filardi, Davide and Vernich, Francesca and Mineo, Federico and Mannocchi, Giulio and Tittarelli, Roberta},
title = {Antidepressants and Road Safety: A Forensic Toxicological Perspective Based on Observational Data and Current Evidence},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1118},
doi = {10.3390/ph19071118}
}
EUVIMED